双表型肝细胞癌新亚型的临床病理学研究进展

Research progress on clinicopathology in dual-phenotype hepatocellular carcinoma

双表型肝细胞癌(dual-phenotype hepatocellular carcinoma,DPHCC)是近年报道的肝细胞癌(hepatocellular carcinoma,HCC)的一种新亚型,以组织学上为典型的肝细胞癌但同时表达肝细胞癌和肝内胆管癌(intrahepatic cholangiocarcinoma,ICC)的基因标志物为特征,因其具有HCC和ICC的双重生物学行为,恶性程度更高,临床预后差,因而正确诊断十分重要。CK19是DPHCC诊断的重要标志物之一,可以通过多种途径参与DPHCC的发生和恶性生物学行为的调控。本文拟从DPHCC的临床病理特点、免疫组织化学标记、组织起源发生等方面对DPHCC的研究进展进行综述。

Dual-phenotype hepatocellular carcinoma （DPHCC） is a novel subtype of hepatocellular carcinoma （HCC）. DPHCC presents the classical morphology of HCC but simultaneously expresses the biomarkers of HCC and intrahepatic cholangiocarcinoma （ICC）. Accu-rate diagnosis of DPHCC is necessary because of its combined biological behaviors of HCC and ICC, highly malignant degree, and in-faust clinical prognosis. CK19 is an important marker of DPHCC and regulates the clonal origin and biological behavior of DPHCC in vari-ous pathways. In this paper, we reviewed the research progress of DPHCC focusing mainly on its clinicopathological features, immuno-histochemical biomarkers, and histogenesis.